Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes
| Autor: | Muhammad Raja, Craig Goldsmith, Benjamin J L Burton, M. Saldana |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Visual acuity genetic structures Visual Acuity Angiogenesis Inhibitors Antibodies Monoclonal Humanized Macular Degeneration Cellular and Molecular Neuroscience Ranibizumab Ophthalmology Age related medicine Humans In patient Aged Aged 80 and over business.industry Antibodies Monoclonal Middle Aged Macular degeneration medicine.disease Verteporfin Choroidal Neovascularization eye diseases Sensory Systems Natural history Clinical trial Treatment Outcome Female sense organs medicine.symptom business medicine.drug |
| Zdroj: | British Journal of Ophthalmology. 94:1543-1545 |
| ISSN: | 0007-1161 |
| DOI: | 10.1136/bjo.2009.174763 |
| Popis: | Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies.1–4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic therapy (PDT), but the treatment comes at a cost.5 The current goal of anti-vascular endothelial growth factor (VEGF) agents is to stabilise and/or improve vision. The natural history of untreated disease leads to irreversible visual loss in majority of patients.6 Current evidence-based literature is lacking for patients with “active, symptomatic” neovascular AMD with centre involvement and visual acuity better than 6/12 (20/40) at presentation. We present 12-month outcomes for neovascular AMD patients treated with Lucentis and presenting baseline visual acuity better than (6/12). Fourteen eyes of 14 patients with neovascular AMD were … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|